¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"myeloid cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • lymphopoietic cell
    ¸²ÇÁ±¸Çü¼º¼¼Æ÷
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • lacunar cell
    °ø°£¼¼Æ÷
  • mitotic cell
    À¯»çºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • mononuclear cell
    ´ÜÇÙ¼¼Æ÷, ´ÜÇÙ±¸
  • mossy cell
    À̳¢¼¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • motor cell
    ¿îµ¿½Å°æ¼¼Æ÷
  • mucous cell
    Á¡¾×¼¼Æ÷
  • mulberry cell
    ¿Àµð¼¼Æ÷
  • multinuclear giant cell
    ´ÙÇÙ°Å´ë¼¼Æ÷, ¹µÇÙ°Å´ë¼¼Æ÷
  • multipolar nerve cell
    ´Ù±Ø½Å°æ¼¼Æ÷, ¹µ±Ø½Å°æ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
  • paralutein cell
    ȲüÁÖÀ§¼¼Æ÷, ºÎȲü¼¼Æ÷
  • parietal cell
    º®¼¼Æ÷
  • pathologic cell
    º´Àû¼¼Æ÷
  • perivascular cell
    Ç÷°üÁÖÀ§¼¼Æ÷
  • phagocytic cell
    Æ÷½Ä¼¼Æ÷
  • pheochrome cell
    ºÎ½Åģũ·Ò¼¼Æ÷
  • photoreceptor cell
    (¢¡visual cell) ½Ã°¢¼¼Æ÷
  • physaliphorous cell
    ´ã°øÆ÷¼¼Æ÷
  • pigment cell
    »ö¼Ò¼¼Æ÷
  • pillar cell
    ±âµÕ¼¼Æ÷
  • pilomotor cell
    Åп½Å°æ¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • pluripotential cell
    ´Ù´É¼º¼¼Æ÷
  • polyhedral cell
    ¹µ¸éü¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • hodgkins disease,lacunar cell in
    ¿­°ø¼¼Æ÷
  • hodgkins disease,reed-sternberg cell in
    ¸®À̵å-½ºÅ׸¥º£¸£±× ¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • huma immunodeficiency virus,follicular dendritic cell infection by
    ¿©Æ÷»ó¼öÁö¼¼Æ÷°¨¿°
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T-cell lymphotrophic virus
    Àΰ£ T¼¼Æ÷ ¸²ÇÁ ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hybrid cell
    ÇÏÀ̺긮µå¼¼Æ÷
  • hybridoma, B cell
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hybridoma, T cell
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • hypercomplex cell
    Ãʺ¹ÇÕ¼¼Æ÷(õ±ÜÜùêá¬øà)
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • cell saver
    Ç÷±¸È¸¼ö±â
  • cell sorting
    ¼¼Æ÷ºÐ·ù
  • cell strain
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell strain
    ¼¼Æ÷ÁÖ(á¬øàñ»).
  • cell substitution
    ¼¼Æ÷ġȯ, Ç÷±¸Àç»ý(Ì´Ë´ ?Ë×).
  • cell substitution
    ¼¼Æ÷ġȯ, Ç÷±¸Àç»ý(úìϹ î¢ßæ).
  • cell surface characteristic
    ¼¼Æ÷Ç¥¸éƯ¼º
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • cell transformation
    ¼¼Æ÷ÇüÁúÀüȯ, ¼¼Æ÷º¯Çü
  • cell typing
    Ç÷±¸Çü°Ë»ç
  • cell wall
    ¼¼Æ÷º®
  • cell wall
    ¼¼Æ÷º®.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
Tc cytotoxic T-cell; the generation time of a cell cycle; tricuspid closure
TCC terminal complement complex; thromboplastic cell component; transitional-cell carcinoma; trichloroca...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
ATL Adult T cell Lymphoma
ATLL Adult T cell Leukemia/Lymphoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
LCL lymphoblastoid cell
LCL B-lymphoid cell lines
BCC Basal Cell Carcinoma
BCNS Basal Cell Nevus Syndrome
BCE Basal cell epithelioma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • null cell
    ´­ ¼¼Æ÷
    B, T ¼¼Æ÷ Ç¥¸é Ç¥Áö¸¦ °¡ÁöÁö ¾ÊÀº ¸²ÇÁ±¸.
  • off-cell pause
    ²¨Áü ¼¼Æ÷ ÁßÁö
  • on-cell
    ÄÑÁü ¼¼Æ÷
  • osteoprogenitor cell
    °ñ Á¶»ó ¼¼Æ÷, »À Á¶»ó ¼¼Æ÷
    1. °ñÀÇ À¯¸® Ç¥¸é ȤÀº ±× ±Ùó¿¡¼­ º¼ ¼ö ÀÖ´Â ºñ±³Àû ¹ÌºÐÈ­µÈ ¼¼Æ÷·Î¼­, ¾î¶² ȯ°æ¿¡¼­´Â ¼¼Æ÷ ºÐ¿­ÇÏ¿© °ñ¾Æ¼¼Æ÷·Î ÀüȯµÇµç°¡ ȤÀº À¶ÇÕÇÏ¿© ÆÄ°ñ ¼¼Æ÷·Î µÇ±âµµ ÇÑ´Ù. 2. ÀÏ¹Ý °ÉÇÕ Á¶Á÷ÀÇ ¼¼Æ÷µé°ú ¸¶Âù°¡Áö·Î °£Áú Á¶Á÷¿¡¼­ À¯·¡ÇÑ ¼¼Æ÷·Î¼­ À¯»ç ºÐ¿­ ´É·Â°ú »À ¼¼Æ÷·Î ºÐÈ­µÉ ¼ö ÀÖ´Â ´É·ÂÀ» °®°í ÀÖ´Ù. Áß°£¿± ¼¼Æ÷¿Í À¯»çÇϸç, ÇÙÀº ¿°±â¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÇ°í ¼¼Æ÷ÁúÀº ¾çÀÌ Àû¾î »ê¼º ¿°·á¿¡ ¹Ì¾àÇÏ°Ô ¿°»öµÈ´Ù.
  • oxyntic cell
    »ê ºÐºñ¼º ¼¼Æ÷
    »ê ºÐºñ¼ºÀÇ À§º® ¼¼Æ÷¿Í °°ÀÌ »êÀ» ºÐºñÇÏ´Â ¼¼Æ÷.
  • oxyphil cell
    È£»ê¼º ¼¼Æ÷
  • oxyphilic cell
    È£»ê ¼¼Æ÷, È£»ê¼º ¼¼Æ÷
  • packed cell volume
    ÃæÀü ¼¼Æ÷ ¿ëÀû
  • packed red blood cell
    ³óÃà ÀûÇ÷±¸, ÃæÀü ÀûÇ÷±¸
    1. Ç÷¾×À» ¿ø½É ºÐ¸®ÇßÀ» ¶§ ¹Ù´Ú¿¡ ¹ÐÁýÇØ ÀÖ´Â °Í, ÃæÀü ÀûÇ÷±¸ ºÎÇǸ¦ Ç츶ÅäÅ©¸®Æ®¶óÇÑ´Ù. 2. hematocrit °ü¿¡ äÃëÇÑ ÀüÇ÷À» ÃÖ´ë·Î ¿ø½É ºÐ¸®ÇÏ¿© ¾ò¾îÁö´Â ÀûÇ÷±¸ÀÇ Ä§ÀüÃþ.
  • paneth cell
    È£»ê¼º °ú¸³ ¼¼Æ÷
  • papillary squamous cell carcinoma
    À¯µÎ»ó ÆíÆò »óÇÇ ¼¼Æ÷¾Ï
  • parafollicular cell
    ºÎ¿©Æ÷ ¼¼Æ÷
  • parasympathetic nerve cell
    ºÎ±³°¨ ½Å°æ ¼¼Æ÷
  • parietal cell
    º® ¼¼Æ÷, ¿Üº® ¼¼Æ÷, º®Ãø ¼¼Æ÷
    1. À§ÀåÀÇ À§Ã¼¹«¿¡ ÀÖ´Â ¼±ÀÇ neck°ú isthmus¿¡ ¸¹ÀÌ ºÐºñÇϸç, ¿°»êÀ» ºÐºñÇÑ´Ù. 2. À§¾× Áß ¿°»êÀÇ ¿øÃµÀÌ µÇ´Â Å« Ÿ¿ø»ó ¶Ç´Â Ãßü»óÀÇ ¼¼Æ÷. À§¼± º®À» µû¶ó »êÀçÇϰí, °¡´Ã¾îÁø ¾ç´ÜÀº ÁÖ¼¼Æ÷ »çÀÌ¿¡ ³¢¾î ÀÖ´Ù.
  • pericellular cell
    ¼¼Æ÷ ÁÖÀ§ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
cell biology <study> The study of the internal workings of cells at the microscopic and molecular level - it is closely linked to molecular biology.
(16 Dec 1997)
cell body Used in reference to neurons, the main part of the cell around the nucleus excluding long processes such as axons and dendrites.
(18 Nov 1997)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
renal cell cancer Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine. Also called renal cell carcinoma.
(12 Dec 1998)
renal cell carcinoma <oncology, tumour> The most common form of kidney cancer which occurs when the cells lining the renal tubule undergo cancerous changes. There are approximately 18,000 new cases of renal cell carcinoma (hypernephroma) per year in the U.S. With about 8,000 deaths annually.
Smoking is considered a major risk factor. Kidney dialysis patients are at increased risk for the development of hypernephroma. Family history for renal cell carcinoma is also considered a risk factor.
Symptoms include haematuria, flank pain, abdominal pain, back pain, weight loss and abdominal swelling.
(27 Sep 1997)
cell bridges Slender cytoplasmic strands connecting adjacent cells; in histological sections of the epidermis and other stratified squamous epithelia, the bridge's are processes attached by a desmosome and are shrinkage artifacts of fixation; true bridge's with cytoplasmic confluence exist between incompletely divided germ cells.
Synonym: cell bridges, cytoplasmic bridges.
(05 Mar 2000)
cell centre Microtubule organising centre of the cell, the pericentriolar region.
(18 Nov 1997)
cell cloning The process of producing a group of cells (clones), all genetically identical, from a single ancestral cell.
(12 Dec 1998)
cell communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP.
(12 Dec 1998)
cell compartmentation A partitioning within cells due to the selectively permeable membranes which enclose each of the separate parts, e.g., mitochondria, lysosomes, etc.
(12 Dec 1998)
cell count A count of the number of cells of a specific kind, usually measured per unit volume of sample.
(12 Dec 1998)
cell culture General term referring to the maintenance of cell strains or lines in the laboratory.
(18 Nov 1997)
cell cycle <cell biology, molecular biology> The sequence of events between mitotic divisions. The cycle is conventionally divided into G0, G1, (G standing for gap), S (synthesis phase during which the DNA is replicated), G2 and M (mitosis).
Cells that will not divide again are considered to be in G0 and the transition from G0 to G1 is thought to commit the cell to completing the cycle and dividing.
(26 Mar 1998)
cell cycle proteins Proteins that control the cell division cycle. This family of proteins includes a wide variety of classes, including cyclin-dependent kinases, mitogen-activated kinases, cyclins, and phosphoprotein phosphatases (phosphoprotein phosphatase) as well as their putative substrates such as chromatin-associated proteins, cytoskeletal proteins, and transcription factors.
(12 Dec 1998)
cell cycle restriction point <cell biology, molecular biology> A point, late in G1, after which the cell must, normally, proceed through to division at its standard rate.
(26 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á